Verona Pharma price target raised to $42 from $36 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Verona Pharma (VRNA) to $42 from $36 and keeps a Buy rating on the shares post the Q3 ...
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more ...
pharmaphorum1d
Verona cuts $400m loan deal as it preps COPD drug for market
Verona Pharma has agreed a new $400 million debt facility with Oxford Finance and Hercules Capital designed to help the company navigate the possible approval and launch of ensifentrine ...
Business Insider1d
Verona Pharma price target raised to $44 from $37 at Canaccord
Canaccord raised the firm’s price target on Verona Pharma (VRNA) to $44 from $37 and keeps a Buy rating on the shares. The firm said they reported Q3 results and noted Ohtuvayre initial sales beat ...
Verona Pharma to Present at Jefferies London Healthcare Conference
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company ...
pharmaphorum2d
Verona cues up filings for COPD drug after it aces phase 3 test
UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.